Liver and biliary tract cancer trials in China

In China 616 Also abroad 1314

616 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
Where
Harbin, Shenyang, Yanji
Age
18 years to 80 years
People
32
Run by
Haibo Shao
See details and how to joinNCT07557914
No phaseTaking people
Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma
Where
Shanghai
Age
18 years to 80 years
People
100
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT07734857
No phaseTaking people
Anatomic Versus Nonanatomic Liver Resection After Conversion Therapy for Hepatocellular Carcinoma
Where
Guangzhou
Age
18 years to 75 years
People
874
Run by
Sun Yat-sen University
See details and how to joinNCT07927452
No phaseTaking people
Preoperative Right Hepatic Artery Embolization for Locally Advanced Bismuth IIIb and IV Perihilar Cholangiocarcinoma
Where
Guangzhou
Age
18 years to 80 years
People
33
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07326189
Phase 2Not yet taking people in China
NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
Where
Shanghai
Age
18 years to 75 years
People
35
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT07919717
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Beijing, Changsha, Hangzhou, Shanghai
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 1Taking people
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Where
Shanghai
Age
18 years and over
People
340 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00
Phase 3Not yet taking people in China
Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer
Where
Zhengzhou
Age
18 years and over
People
90
Run by
Zhai Wenlong
See details and how to joinNCT07916844
No phaseTaking people
Photodynamic Therapy Combined With a Self-expandable Radioactive Particle-loaded Biliary Stent for Unresectable Extrahepatic Cholangiocarcinoma
Where
Zhengzhou
Age
18 years and over
People
30
Run by
Zhai Wenlong
See details and how to joinNCT07916870
No phaseNot yet taking people in China
Integration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.
Where
Chengdu
Age
18 years and over
People
380
Run by
West China Hospital
See details and how to joinNCT07912853
No phaseNot yet taking people in China
Prospective AI-Assisted Screening of Biliary Tract Cancer Using Non-Contrast CT
Where
Beijing
Age
18 years and over
People
10,000
Run by
Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT07911397
Phase 2/3Taking people
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
Where
Guangzhou
Age
18 years to 75 years
People
66
Run by
Guangzhou Virotech Pharmaceutical Co., Ltd.
See details and how to joinNCT07589244
Phase 1/2Taking people
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Where
Beijing, Changsha, Chengdu, Fuzhou, Shanghai, Wuhan
Age
18 years and over
People
220 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06428409 · EU 2023-508703-21-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Beijing, Changsha, Chengdu, Dongguan, Henan, Hubei, Shanghai, Shenyang, Wuhan, Xi'an, Xinxiang, Xuzhou
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 3Not yet taking people in China
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
Where
Nanjing, Shanghai
Age
18 years to 75 years
People
690
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07691762
Phase 3Taking people
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Where
Beijing, Changchun, Changsha, Chengdu, Harbin, Hefei, Jinan, Lanzhou, Shanghai
Age
18 years and over
People
286 worldwide
Run by
Jazz Pharmaceuticals
See details and how to joinNCT06282575 · EU 2023-508219-21-00
Phase 2Taking people
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial
Where
Nanjing
Age
18 years to 75 years
People
81
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07847710
Phase 2Taking people
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Where
Guangzhou
Age
18 years to 75 years
People
105
Run by
Sun Yat-sen University
See details and how to joinNCT07487662
Phase 3Not yet taking people in China
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Where
Changsha, Chengdu, Ganzhou, Guangzhou, Hangzhou, Jiangmen, Jinan, Jinhua, Lishui, Ningbo, Qingdao, Ürümqi, Wuhan
Age
18 years and over
People
140
Run by
Zhejiang Cancer Hospital
See details and how to joinNCT07691515
Phase 2Enrolling by invitation
Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract Cancer
Where
Jiangmen
Age
18 years to 80 years
People
30
Run by
Jiangmen Central Hospital
See details and how to joinNCT07890311
Phase 2Taking people
Phase II Study of Primary Tumor Resection and Selective Lymph Node Dissection Followed by RT for BTC With Lymph Node Metastases
Where
Beijing
Age
18 years to 80 years
People
73
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07893392
No phaseTaking people
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
Where
Beijing
Age
18 years to 80 years
People
470
Run by
Sun Yat-sen University
See details and how to joinNCT06644430
Phase 1/2Taking people
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Where
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nanyang, Shanghai, Xi'an
Age
18 years and over
People
198 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07291076 · EU 2025-523602-33-00
Phase 2Not yet taking people in China
Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC
Where
Nanjing
Age
18 years and over
People
41
Run by
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT07890506
Phase 1/2Taking people
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Where
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Taizhou, Tianjin, Wuhan, Xi’an, Xinxiang, Zhengzhou
Age
18 years and over
People
862 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT05914116